title: Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase.
abstract: BACKGROUND AND METHODS: Growth failure is characteristic of untreated mucopolysaccharidosis type VI (MPS VI: Maroteaux-Lamy syndrome). Growth was studied in fifty-six MPS VI patients (5 to 29 years old) prior to and for up to 240 weeks of weekly infusions of recombinant human arylsulfatase B (rhASB) at 1 mg/kg during Phase 1/2, Phase 2, Phase 3 or Phase 3 Extension clinical trials. Height, weight, and Tanner stage data were collected. Pooled data were analyzed to determine mean height increase by treatment week, growth impacts of pubertal status, baseline urinary GAG, and age at treatment initiation. Growth rate for approximately 2 years prior to and following treatment initiation was analyzed using longitudinal modeling. RESULTS: Mean height increased by 2.9 cm after 48 weeks and 4.3 cm after 96 weeks on enzyme replacement therapy (ERT). Growth on ERT was not correlated with baseline urinary GAG. Patients under 16 years of age showed greatest increases in height on treatment. Model results based on pooled data showed significant improvement in growth rate during 96 weeks of ERT when compared to the equivalent pretreatment time period. Delayed pubertal onset or progression was noted in 10 patients entering the clinical trials; all of whom showed progression of at least one Tanner stage during 2 years on ERT, and 6 of whom (60%) completed puberty. CONCLUSION: Analysis of mean height by treatment week and longitudinal modeling demonstrate significant increase in height and growth rate in MPS VI patients receiving long-term ERT. This impact was greatest in patients aged below 16 years. Height increase may result from bone growth and/or reduction in joint contractures. Bone growth and resolution of delayed puberty may be related to improvements in general health, bone cell health, nutrition, endocrine gland function and reduced inflammation.
authors.affiliation: BioMarin Pharmaceutical Inc, Novato, CA, USA.
authors.forename: Celeste
authors.initials: C
authors.lastname: Decker
authors.forename: Zi-Fan
authors.initials: ZF
authors.lastname: Yu
authors.forename: Roberto
authors.initials: R
authors.lastname: Giugliani
authors.forename: Ida Vanessa D
authors.initials: IV
authors.lastname: Schwartz
authors.forename: Nathalie
authors.initials: N
authors.lastname: Guffon
authors.forename: Elisa Leão
authors.initials: EL
authors.lastname: Teles
authors.forename: M Clara Sá
authors.initials: MC
authors.lastname: Miranda
authors.forename: J Edmond
authors.initials: JE
authors.lastname: Wraith
authors.forename: Michael
authors.initials: M
authors.lastname: Beck
authors.forename: Laila
authors.initials: L
authors.lastname: Arash
authors.forename: Maurizio
authors.initials: M
authors.lastname: Scarpa
authors.forename: David
authors.initials: D
authors.lastname: Ketteridge
authors.forename: John J
authors.initials: JJ
authors.lastname: Hopwood
authors.forename: Barbara
authors.initials: B
authors.lastname: Plecko
authors.forename: Robert
authors.initials: R
authors.lastname: Steiner
authors.forename: Chester B
authors.initials: CB
authors.lastname: Whitley
authors.forename: Paige
authors.initials: P
authors.lastname: Kaplan
authors.forename: Stuart J
authors.initials: SJ
authors.lastname: Swiedler
authors.forename: Susan
authors.initials: S
authors.lastname: Conrad
authors.forename: Paul
authors.initials: P
authors.lastname: Harmatz